All In MedTech

Device Trial Radar · NCT05972889

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

Randomized Blinded Evaluation of the Effects of Transcutaneous Electrical Nerve Stimulation and Interferential Current Compared to a Sham Device and Standard of Care in Patients With Non-Specific Chronic Lower Back Pain

Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

334

Actual

Start

Nov 2, 2023

Primary completion

Oct 21, 2025

Study completion Oct 21, 2025

Sponsor

Lead sponsor
Zynex Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 2, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, sham-controlled, randomized, single-blinded, multi-center study comparing two different modes of the NexWave device, transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC), with an identical non-functioning NexWave sham device or self-defined standard of care for improvement of pain intensity of non-specific CLBP.

Conditions

  • Non-Specific Chronic Lower Back Pain

Interventions

  • NexWaveDevice

    Device subjects receive designated treatment mode twice daily for up to 8 weeks.

  • ShamDevice

    Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analogue Scale Pain Rating - NexWave vs. ShamTime frame: Four weeks

1 more outcomes with a free account

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • DBPS Research

    Greenwood Village, Colorado

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.